Skip to content

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Relationship Between Intraoperative Intravenous Acetaminophen and Postoperative Opioid Avoidance for Ambulatory Surgical Procedures

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Relationship Between Intraoperative Intravenous Acetaminophen and Postoperative Opioid Avoidance for Ambulatory Surgical Procedures

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01231191
Acronym
Cadence
Enrollment
0
Registered
2010-11-01
Start date
Unknown
Completion date
Unknown
Last updated
2012-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain, Intraoperative and Postoperative Opioid Requirements

Brief summary

This is a research study to determine if giving acetaminophen intravenously in hte operating room will decrease the number of patients who require additional pain medicine, such as morphine, after surgery in the recovery room.

Detailed description

Primary Specific Aim: To determine if adding an intraoperative dose of intravenous acetaminphen to usual and customary analgesics during ambulatory surgery impacts the proportion of patients remaining opioid-free in the post-anesthesia recovery room. Hypothesis: Adding an intraoperative dose of intravenous acetaminophen to usual and customary analgesics during ambulatory surgery increases the proportion of patients remaining opioid-free in the post-anesthesia recovery room. Secondary Specific Aim: To determine if adding an intraoperative dose of intravenous acetaminophen to usual and customary analgesics during amublatory surgery impacts the required doses of additional perioperative analgesics. Hypothesis: Adding an intraoperative dose of intravenous acetaminophen to usual and customary analgesics during ambulatory surgery decreases the required doses of additional analgesics in both the operating room and post-anesthesia recovery room.

Interventions

Acetaminophen 1000 mg administered over 15 minutes intravenously as soon as feasible intraoperatively.

DRUGIntravenous placebo

Normal saline administered over 15 minutes intravenously as soon as feasible intraoperatively.

Sponsors

Cadence Pharmaceuticals
CollaboratorINDUSTRY
University of California, San Diego
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Undergoing ambulatory surgery under general anesthesia * Expected postoperative pain to be mild-moderate * Age 18 years or older * Have an ASA physical status or 1, 2, or 3

Exclusion criteria

* Anticipated peripheral or neuraxial nerve block * Any physical, mental or medical conditions which may confound quantifying postoperative pain resulting from surgery * Current chronic opioid or tramadol use * History of alcohol or opioid abuse * Known allergy to the study medications * Pregnancy * Any health condition requiring greater than 100 micrograms of fentanyl during anesthesia induction * Treated with any acetaminophen-containing medication in the previous 8 hours * Treated with MAO inhibitors within 10 days prior to surgery * Inability to communicate with the investigators and hospital staff * Known or impaired liver function

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the difference in proportions of patients from each treatment group who avoid using any opioids following anesthesia emergence until recovery room discharge.Day of Surgery

Secondary

MeasureTime frame
A secondary outcome for this investigation will be the total dose of ibuprophen administered to the patient.Day of Surgery
A secondary outcome measure for this investigation will be the total dose of oxycodone administered to the patient.Day of Surgery
A secondary outcome measure will be any surgeon-administered local anesthetics used for wound infiltration.Day of Surgery
A secondary outcome measure for this study will be any recovery-room anti-emetics administered to the patient.Day of Surgery
A secondary outcome for this investigation will be the total dose of morphine administered to the patient.Day of Surgery
A secondary endpoint for this investigation will be the total dose of fentanyl administered to the patient.Day of Surgery
Patients will be asked at time of PACU discharge, Overall, how would you rate the level of pain relief from study medication? Responses will be on 0 to 3 scale where 0=poor and 3=excellent.Day of Surgery
Adverse eventsUp to one year postoperative
Patients will be asked at time of PACU discharge, Overall, how would you rate the study treatments? Responses will be on 0 to 3 scale where 0=poor and 3=excellent.Day of Surgery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026